Sun, Feb 1, 2015, 6:10 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

fenix1357 60 posts  |  Last Activity: Jan 20, 2015 1:18 PM Member since: May 28, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Recordati

    by whynotnymox Nov 18, 2014 1:56 PM
    fenix1357 fenix1357 Nov 20, 2014 11:51 AM Flag

    Usually when I am long a stock I pay more attention to the posters who are short as it is a good way to question your assumptions and see if you are wrong but on thus board I have decided to put wrb, munkus and howabout on ignore. They are the same person with the same uninspiring intellect and paranoid fantasies and contribute nothing to my understanding.

    A basic statistical primer-If you toss a coin 4 times and it comes up heads all 4 times, the odds of doing that are one in sixteen or around.0625. This implies the odds that the coin is biased in some way is pretty high. In clinical trails we put significance at .05 so if the drug was higher than placebo at all 4 points there is a good possibility it works. Proven beyond doubt -no but good possibility-yes.

    As to all the paranoid fantasies its worth pointing out the person who has lost the most is Dr.A; he now owns 1/3 of a co. which is worth 18 million now and before was worth 200 million. Do the maths.

  • Reply to

    Recordati

    by whynotnymox Nov 18, 2014 1:56 PM
    fenix1357 fenix1357 Nov 18, 2014 10:54 PM Flag

    I emailed them twice (Recordati) and got a prompt response each time (unlike Nymox which still has not responded to my E mail from two weeks ago).
    They still have not received the data from NYMOX and the trial will continue until they can review the data. They have no anticipated date by which they will receive the data.

    Reading between the lines it appears the bulk of the money has been spent so they would rather continue the trial as if successful they can get EU approval based just on this trial. The chances of this trial succeeding are greater because its a single blinded trail which historically has a less placebo effect than a double blinded trail which was the case with the US trials.

    The NYMOX trials as per the conference call showed better results with the drug than placebo at all points 90,180,270 and 365 days although not statistically significant. This is good presumptive evidence of statistical significance. If you toss a coin 4 times, the chances of it coming up heads all four times in only 0.0625 a fairly low probability number. This seems to suggest the drug works and a better designed trial could succeed.

  • Reply to

    Pitiful -

    by stock1trader1a1 Nov 15, 2014 6:06 AM
    fenix1357 fenix1357 Nov 17, 2014 9:05 AM Flag

    You guys are the ones doing all the end zone dancing. WRB even has a new moniker to pat himself on the back because no one else will.

  • Reply to

    Pitiful -

    by stock1trader1a1 Nov 15, 2014 6:06 AM
    fenix1357 fenix1357 Nov 16, 2014 4:18 PM Flag

    I was not going to post here again but with all the misinformation posted by how howabout gas bag, wrb and monkeyfuss I felt I had to.
    Let me explain to you why the $100,000 was raised. It was to demonstrate that their long term funding agreement with LG is intact and this could be put in the 6K. Notice the 6K does not have a "going concern" statement by the auditor and this $100,000 draw is the reason why. This is why the stock went up when the 6K was released and will hopefully go up some more so no dilution or reverse split will be needed.
    This is dead money for a while but as I said in my previous post but should go up in 2016.

  • Reply to

    sell or hold?

    by brokenrecordat895 Nov 22, 2014 9:16 PM
    fenix1357 fenix1357 Nov 25, 2014 1:53 PM Flag

    There are positives and negatives to holding.
    The positives are their financing agreement is holding so money is not a problem and so no reverse splits and dilution. The selling also seems to have abated and this seems to be the bottom price.
    Other positives are that the BPH trial in Europe is still going on and looks it will be completed. Since the drug was effective but failed to show statistical significance against the placebo and this placebo is different (not as powerful as historically injectable placebos are more powerful), there is a fair chance this study will be positive. Based on this study if positive they can hope to get EU approval and also possibly sell it in Asia/Africa and USSR. Also they can elect to do a small trial in US with run in to minimize the placebo effect (if they have the financing). This trial will have small numbers and hopefully only be for six months as the drug can get approved on a six month study .
    Another positive is the cancer indication. Its hard to be sure because they do not release any topline data but if they proceed with another trial for this or get some collaboration it will be an indication (hopefully ) that the numbers were meaningful in the first trial. I suspect LG will also demand more accountability after this current fiasco.

    The negatives are Dr. A and Dr. A and Dr.A. He has not conducted himself as a proper CEO. Just a shell shocking announcement with no further conference calls to explain further measures the company is taking to boost shareholder value. His paranoia and secrecy with no release of details is harming the company.

    There, you have my two bits :)

  • Reply to

    Recordati

    by whynotnymox Nov 18, 2014 1:56 PM
    fenix1357 fenix1357 Nov 20, 2014 1:25 PM Flag

    Dr. Shore has had no association with NYMOX for the last few years. He is touting another co. now. See my previous post from a few months back below.

    The reason he said this was because he is now touting an alternative BPH treatment (See below) which does not involve needles.. He is a paid consultant; he endorses whatever procedure he is currently performing. I am glad he did not put down NX 1207 for any other reason. Your honesty is appreciated. Thanks.

    Click here for an article on sexual function and BPH by Neal D. Shore, MD, Myrtle Beach, South Carolina. Dr. Shore is a clinical urologist and principle investigator of the Prolieve Thermodilatation® System, who specializes in prostate disease and has performed more than 200 office-based minimally invasive treatments for the symptoms of BPH. This article is based on Dr. Shore's clinical experiences and opinions. Dr. Shore is a paid consultant of Boston Scientific.

  • Reply to

    Bankruptcy inevitable.

    by aquasolutions4u Jan 7, 2015 7:59 AM
    fenix1357 fenix1357 Jan 7, 2015 11:52 AM Flag

    It is more honest for you to post under your real name WRB; all of us know this is you.
    One thing the Co. is not doing is going bankrupt; they have zero debt and covenant with LG which seems to be working.

  • Reply to

    THE DRUG WORKED

    by longmox Nov 6, 2014 9:37 AM
    fenix1357 fenix1357 Nov 6, 2014 10:56 AM Flag

    Stay calm. The data is being looked at closely before a decision is made. It is unfortunately at least going to be a few weeks/months before we know what is happening. I would not be surprised at another small trial with some tweaking. If you want to see a similar stock with a good ending look at ACAD.

  • Reply to

    We deserve better

    by whynotnymox Nov 7, 2014 9:03 AM
    fenix1357 fenix1357 Nov 7, 2014 12:00 PM Flag

    Good advice. I will start with an E mail.
    The conference call was surreal. I intend to get to the bottom this even if I have to spend some cash. I want the topline numbers both for this and the prostate cancer trial and feel I am entitled to it.

  • Reply to

    conference call

    by how_bout_we_talk Nov 3, 2014 6:35 PM
    fenix1357 fenix1357 Nov 3, 2014 7:48 PM Flag

    Qs. is will Recordati continue their trial, if so this drug can be resuscitated. In the conference call he was inclined to do the prostate cancer study and it was obvious he had thought about it as he could even quantify the cost of the study as being 3-6 million dollars. He also said they had afinnacing in place witha solid partner so it seems he has talked to LG about it.

  • Reply to

    We deserve better

    by whynotnymox Nov 7, 2014 9:03 AM
    fenix1357 fenix1357 Nov 7, 2014 9:12 AM Flag

    I am willing to contribute to hiring a lawyer to get Dr. A to answer these questions. If enough people are we may be able to get some answers.

  • fenix1357 fenix1357 Jan 7, 2015 12:31 PM Flag

    What did Paul tell you is going to happen in these 30 days. He wants the price up so the class action suit can be dismissed. Is he finally going to sign a deal for prostate cancer or come out and tell us the drug works for a subsection of the population?

  • fenix1357 fenix1357 Jan 13, 2015 7:12 PM Flag

    Can't wait to see the summary of results etc !

    NYMX in its entire existence has never published results of any trial. This is one of the reasons people think it is a scam.

  • Reply to

    for looky

    by how_bout_we_talk Nov 3, 2014 10:59 AM
    fenix1357 fenix1357 Nov 3, 2014 1:16 PM Flag

    From the sounds of it he is not going to pursue the BPH indication, he and LG do not have the stamina or financial resources. It will be interesting to see the Urine flow and prostate volume results. I think that will determine if Recordati continues with the trial.
    From the PR seems he might be considering a shot at a phase three for early prostate cancer. Its quick and LG might pay for it. Although the phase two was a flop because of placebo again; its not unusual for that to happen in phase two and a better designed phase three could be considered.

  • Reply to

    Whynotnymox: Placebo vs NX-1207

    by munkus16 Nov 25, 2014 6:50 AM
    fenix1357 fenix1357 Nov 26, 2014 1:13 PM Flag

    Antibiotic was given for three days and data was not collected until 90, 180, 270 days later. IMHO this antibiotic thing is not a big deal. All injectable placebos have big effects especially as I am sure there were cognitively challenged patients ( Recruiting was hard and I am sure no attempt was made to screen out people with alzheimers or other cognitive biases.). Having an injection and then seeing blood in your urine would convince them they had the actual drug.
    Agree Recordati has been recruiting for a year and there should be enough data for an interim analyses; certainly warranted. Also needed is for Dr. A to reveal all data, this paranoia is nonsense!
    I do think there was a signal for efficacy in the data if the drug was superior to placebo at all points in time and if Recordati interim analysis is positive grounds for a redesigned study. Also need some professional statisticians to look at the data and go over how it was collected and analysed and see if there are enough grounds to throw out the outliers in the placebo group.

    Dr. A do the job or step down.

  • fenix1357 fenix1357 Nov 6, 2014 7:52 PM Flag

    I was looking for an answer to a question you posed previously about the utility of this drug for early prostate cancer.

    I refer you to the latest study I could find it was 2011 from John Hopkins of 769 men with early prostate cancer (less than Gleason grade6). In that study about 1/3 progressed over time. You can find it at the John Hopkins Site.

    In the US 217000 men are diagnosed with low grade prostate cancer and 90% including 80% of those over 75 years choose a treatment instead of surveillance.

    It does seem NX1207 will have a huge market at least in the US for this indication.

  • Reply to

    for looky

    by how_bout_we_talk Nov 3, 2014 10:59 AM
    fenix1357 fenix1357 Nov 3, 2014 2:03 PM Flag

    Good Plan. If he pursues the prostate cancer indication without much dilution (with LG support) it might go up more than that next year.

  • fenix1357 fenix1357 Nov 4, 2014 6:56 PM Flag

    Thanks. I am not counting on the BPH treatment but seems he is going to go ahead and try for the low grade early prostate cancer. Hopefully he will get good results; the problem is there is not a clear indication for treating it although as he said in the conf. call, a lot of people get it treated and over with. Hopefully I will be able to get out then but this is dead money till then unless Recordati continues their trial and comes out with good results.

  • Reply to

    conference call

    by how_bout_we_talk Nov 3, 2014 6:35 PM
    fenix1357 fenix1357 Nov 5, 2014 8:10 PM Flag

    I read this post of your today for the first time. Remember ACAD they had the same problem but good results in certain aspects , so they did another study just looking at those aspects and carefully trained the people recording the responses so they would get accurate results and the rest is history.
    This could very well go the same way if Recordati or another big pharma offered to run another trial in exchange for US rights (for agreed upon royalties).

  • Reply to

    Recordati

    by whynotnymox Nov 18, 2014 1:56 PM
    fenix1357 fenix1357 Nov 18, 2014 6:36 PM Flag

    I emailed them twice (Recordati) and got a prompt response each time (unlike Nymox which still has not responded to my E mail from two weeks ago).
    They still have not received the data from NYMOX and the trial will continue until they can review the data. They have no anticipated date by which they will receive the data.

    Reading between the lines it appears the bulk of the money has been spent so they would rather continue the trial as if successful they can get EU approval based just on this trial. The chances of this trial succeeding are greater because its a single blinded trail which historically has a less placebo effect than a double blinded trail which was the case with the US trials.

    The NYMOX trials as per the conference call showed better results with the drug than placebo at all points 90,180,270 and 365 days although not statistically significant. This is good presumptive evidence of statistical significance. If you toss a coin 4 times, the chances of it coming up heads all four times in only 0.0625 a fairly low probability number. This seems to suggest the drug works and a better designed trial could succeed.

NYMX
0.39-0.01(-2.50%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gran Tierra Energy, Inc.
AMEXFri, Jan 30, 2015 4:01 PM EST
Hawaiian Holdings Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST